Merck has announced a new licensing agreement with Inspirna for ompenaclid, a first-in-class treatment currently in phase 2 development for RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).
At Veeva R&D and Quality Summit 2023, Bio Pharma Reporter caught up with Courtney Gilbert, senior director, business system management and innovation, PV operations and global process enablement, at Merck.
AbbVie is acquiring rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment Elahere, which was granted accelerated approval from the FDA last year.
An mRNA cancer vaccine, in combination with Keytruda, reduced the risk of recurrence or death in melanoma patients by 44% compared to Keytruda alone, according to Phase 2b data. Merck and Moderna plan to initiate a Phase 3 study in the coming months.
Merck will acquire Prometheus Biosciences, a San Diego biotech working on a precision medicine approach for developing therapeutics for the treatment of immune-mediated diseases.
OPKO Health’s ModeX Therapeutics has entered into an exclusive worldwide license and collaboration agreement with Merck to develop MDX-2201, ModeX’s preclinical nanoparticle vaccine candidate targeting EBV.
Merck has signed a Memorandum of Understanding (MoU) with Synplogen, a startup spun out of Kobe University's Graduate School of Science, Technology and Innovation.
BigHat Biosciences, a US biotech with a machine learning-guided antibody discovery and development platform, has announced a collaboration with Merck to apply its technology to design candidates for up to three drug discovery programs.
Merck has exercised its option to jointly develop and commercialize a personalized cancer vaccine (PVC) with Moderna following 'significant progress' made by the two companies in the field to date.
Merck and Orna Therapeutics have announced a collaboration agreement to discover, develop and commercialize Orna’s next generation oRNA technology across multiple programs, including vaccines and therapeutics in infectious disease and oncology.
The pharmaceutical company has inked a strategic collaboration with the drug discovery firm, centering on uncovering novel targets in Alzheimer’s disease.
Millipore Sigma has launched its VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform: meaning the CDMO can now provide a full viral vector manufacturing offering including AAV, Lentiviral, CDMO, CTO, and process development.
With speculation that Merck is lining up a multi-billion dollar acquisition in the ADC space, the company has agreed a second collaboration deal with Sichuan Kelun Pharmaceutical.
Merck (MSD outside the US and Canada) is welcoming applications from early-stage biomedical start-ups for its newly launched Merck Digital Sciences Studio (MDSS): which seeks to support technologies for drug discovery and development.
The antibody drug conjugate market has had a busy few years, as the appetite for acquisitions of ADC-specialists began to grow, with Gilead buying Immunomedics and Merck acquiring VelosBio.
The pharmaceutical company is expanding its alliance with historically Black medical schools to bolster the battle against systemic health disparities.
Merck has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, Wisconsin, US.
Merck is collaborating with Agilent Technologies to plug what it calls a critical gap within downstream processing for process analytical technologies (PAT).
The Biotechnology Innovation Organization elected the fresh slate of leaders during the BIO International Convention, taking place in San Diego this week.
A single dose of the Human Papillomavirus (HPV) vaccine offers comparable protection to the current two dose schedule, according to a review from the WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) released this week.
Human papillomavirus (HPV) vaccines reduce cervical cancer rates by 87% in women who were offered the jab between the ages of 12-13, according to a study which analysed data from England's HPV vaccine program.
AION Labs, a ‘first-of-its-kind’ innovation lab that will create and adopt AI technology to transform the process of drug discovery and development, has officially launched this month.
Merck and Pfizer subsidiary, Wyeth LLC, have resolved a patent row related to their competing vaccines for preventing diseases including pneumonia and meningitis.
A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.
Merck’s US facilities will help manufacture Johnson & Johnson’s COVID-19 vaccine: which a $268.8m injection from the US government helping it adapt existing facilities for COVID-19 vaccines and medicines.
Merck is shutting down the programs linked to its two COVID-19 vaccine candidates following early trial data indicating that they failed to generate immune responses comparable to a natural infection or existing vaccines.
Merck will acquire Oncolmmune for an upfront payment of $425m: pledging to accelerate the development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19.
Merck and Seattle Genetics have announced two strategic oncology collaborations: one to develop Seattle Genetics’ antibody-drug conjugate ladiratuzumab vedotin worldwide; and another to accelerate the global reach of Tukysa (tucatinib).
The newly separate business will include women’s health, legacy brands, and biosimilar units, as the main part of the business retains oncology, vaccines, hospital and animal health.
Shortly after EMA’s approval, the US FDA follows with a positive nod for Ervebo, the first vaccine to receive approval for the prevention of Ebola virus disease.
Merck announces that it has reallocated Gardasil from the US CDC stockpiles, as a surge in demand sees revenues from the vaccine rise 26% year-on-year.
Merck extends its partnership with 4D Pharma to discover and develop LBP vaccines for three undisclosed indications, adding to their Keytruda partnership.
The news most interesting to our readers were those featuring collaborations, whether in the production of an Ebola vaccine, biosimilars entering new markets or creating new manufacturing modalities.
Unofficial reports suggested that individuals in Tanzania were exhibiting Ebola-like symptoms, but the WHO reports not receiving detailed information from the country.